File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice

TitleTherapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice
Authors
KeywordsHepatitis B virus
Immune tolerance
Therapeutic vaccine
Issue Date2001
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2001, v. 19 n. 30, p. 4219-4225 How to Cite?
AbstractTherapeutic efficacy of HBsAg-anti-HBs-recombinant DNA harboring hepatitis B virus (HBV) S gene complex was compared with three other therapeutic vaccine candidates (recombinant HBsAg, HBsAg complexed to anti-HBs antibodies and naked plasmid DNA encoding the HBV S gene). After four injections at 3-week intervals, the most pronounced decrease of serum HBsAg, the highest titer of anti-HBs response, the highest level of interferon-γ produced by splenocytes and potent cytotoxicity T cell response were observed in the HBsAg-anti HBs-sDNA immunized group. Reduced expression of HBsAg in hepatocytes was also shown. The therapeutic mechanism of HBsAg-anti-HBs-DNA was speculated as modulation of HBsAg presentation via both endogenous and exogenous pathways. © 2001 Elsevier Science Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/148265
ISSN
2021 Impact Factor: 4.169
2020 SCImago Journal Rankings: 1.585
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorZheng, Ben_HK
dc.contributor.authorNg, MHen_HK
dc.contributor.authorHe, LFen_HK
dc.contributor.authorYao, Xen_HK
dc.contributor.authorChan, KWen_HK
dc.contributor.authorYuen, KYen_HK
dc.contributor.authorWen, YMen_HK
dc.date.accessioned2012-05-29T06:11:53Z-
dc.date.available2012-05-29T06:11:53Z-
dc.date.issued2001en_HK
dc.identifier.citationVaccine, 2001, v. 19 n. 30, p. 4219-4225en_HK
dc.identifier.issn0264-410Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/148265-
dc.description.abstractTherapeutic efficacy of HBsAg-anti-HBs-recombinant DNA harboring hepatitis B virus (HBV) S gene complex was compared with three other therapeutic vaccine candidates (recombinant HBsAg, HBsAg complexed to anti-HBs antibodies and naked plasmid DNA encoding the HBV S gene). After four injections at 3-week intervals, the most pronounced decrease of serum HBsAg, the highest titer of anti-HBs response, the highest level of interferon-γ produced by splenocytes and potent cytotoxicity T cell response were observed in the HBsAg-anti HBs-sDNA immunized group. Reduced expression of HBsAg in hepatocytes was also shown. The therapeutic mechanism of HBsAg-anti-HBs-DNA was speculated as modulation of HBsAg presentation via both endogenous and exogenous pathways. © 2001 Elsevier Science Ltd. All rights reserved.en_HK
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_HK
dc.relation.ispartofVaccineen_HK
dc.rightsVaccine. Copyright © Elsevier Ltd.-
dc.subjectHepatitis B virusen_HK
dc.subjectImmune toleranceen_HK
dc.subjectTherapeutic vaccineen_HK
dc.subject.meshAnimalsen_US
dc.subject.meshAntigen-Antibody Complex - Immunologyen_US
dc.subject.meshCytokines - Biosynthesisen_US
dc.subject.meshDna, Recombinant - Immunologyen_US
dc.subject.meshHepatitis B - Therapyen_US
dc.subject.meshHepatitis B Antibodies - Immunologyen_US
dc.subject.meshHepatitis B Surface Antigens - Blood - Immunologyen_US
dc.subject.meshHepatitis B Vaccines - Therapeutic Useen_US
dc.subject.meshLiver - Pathology - Virologyen_US
dc.subject.meshMiceen_US
dc.subject.meshMice, Inbred C57blen_US
dc.subject.meshMice, Transgenicen_US
dc.subject.meshT-Lymphocytes, Cytotoxic - Immunologyen_US
dc.titleTherapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic miceen_HK
dc.typeArticleen_HK
dc.identifier.emailZheng, B: bzheng@hkucc.hku.hken_HK
dc.identifier.emailNg, MH: hrmmnmh@hkucc.hku.hken_HK
dc.identifier.emailChan, KW: hrmtckw@hku.hken_HK
dc.identifier.emailYuen, KY: kyyuen@hkucc.hku.hk-
dc.identifier.authorityZheng, BJ=rp00353en_HK
dc.identifier.authorityChan, KW=rp00330en_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0264-410X(01)00158-Xen_HK
dc.identifier.pmid11457548-
dc.identifier.scopuseid_2-s2.0-0035919599en_HK
dc.identifier.hkuros62046-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035919599&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume19en_HK
dc.identifier.issue30en_HK
dc.identifier.spage4219en_HK
dc.identifier.epage4225en_HK
dc.identifier.isiWOS:000170090200017-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridZheng, BJ=7201780588en_HK
dc.identifier.scopusauthoridNg, MH=7202076421en_HK
dc.identifier.scopusauthoridHe, LF=55074291500en_HK
dc.identifier.scopusauthoridYao, X=34973484500en_HK
dc.identifier.scopusauthoridChan, KW=16444133100en_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK
dc.identifier.scopusauthoridWen, YM=7401776949en_HK
dc.identifier.issnl0264-410X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats